Lipoprotein Subfraction Analysis Using Nuclear Magnetic Resonance Spectroscopy

Markers in Cardiology: A Case-Oriented Approach

Volumn , Issue , 2008, Pages 217-250

  Cromwell, William C ^a,b   Bays, Harold E ^c   Toth, Peter P ^d,e  

^a Presbyterian Center for Preventative Cardiology   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^d Sterling Rock Falls Clinic ^*  (United States)

^e UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Cholesterol; Coronary heart disease; High density lipoprotein; Lipoprotein subfraction analysis; Spectroscopy

Indexed keywords

EID: 72849139699     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470691984.ch19     Document Type: Chapter

References (86)

1. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002;90(suppl):22i-29i.
2. Blake GJ, Otvos JD, Rifai N, Ridker PM. LDL particle concentration and size as determined byNMRspectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930-1937.
3. Mackey RH, Kuller LH, Sutton-Tyrell K, Evans RW, Holubkov R, Matthews KA. Lipoprotein subclasses and coronary artery calcification in postmenopausal women from the Healthy Women Study. Am J Cardiol 2002;90(8A):71i-76i.
4. Rosenson RS, Freedman DS, Otvos JD. Relations of lipoprotein subclass levels and LDL size to progression of coronary artery disease in the PLAC I trial. Am J Cardiol 2002;90:89-94.
5. Kuller L, Arnold A, Tracy R et al. NMR spectroscopy of lipoproteins and risk of CHD in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2002;22:1175-1180.
6. Otvos JD, Collins D, Freedman DS et al. LDL and HDL particle subclasses predict coronary events and are changed favorably by gemfibrozil therapy in the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2006;113:1556-63.
7. Schaefer E, Parise H, Otvos J, McNamara J, D'Agostino R, Wilson P. LDL particle number, size, and subspecies in assessing cardiovascular risk: results from the Framingham Offspring Study. Circulation 2004;110:III-777.
8. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. In: Rifai N,Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. AACC Press, Washington, DC, 2000:609-623.
9. Otvos J, Jeyarajah E, Bennett D. Aspectroscopic approach to lipoprotein subclass analysis. J Clin Ligand Assay 1996;19:184-189.
10. Lounila J, Ala-Korpela M, Jokisaari J. Effects of orientational order and particle size on the NMR line positions of lipoproteins. Phys Rev 1994;72:4049-4052.
11. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002;48:171-180.
12. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004;6:381-387.
13. Garvey WT, Kwon S, Zheng D et al. The effects of insulin resistance and type 2 diabetes mellitus on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-462.
14. Goff DC, D'Agostino RB, Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005;54:264-270.
15. Festa A, Williams K, Hanley AJG et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2005;111:3465-3472.
16. Otvos J. Measurement of triglyceriderich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardiol 1999;22(6 suppl):II21-II27.
17. Otvos JD. Why cholesterol measurements may be misleading about lipoprotein levels and cardiovascular disease risk-clinical implications of lipoprotein quantification using NMR spectroscopy. J Lab Med 2002;26:544-550.
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
19. Kathiresan S, Otvos JD, Sullivan LM et al. Increased small LDL particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006;113:20-29.
20. Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol<100 mg/dl. Am J Cardiol. 2006 Dec 15;98(12):1599-602.
21. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339-349.
22. Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000;2:200-207.
23. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363-1379.
24. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, pathophysiology, and therapeutic aspects. Diabetes Metab 1999;25:199-211.
25. McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, SchaeferEJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Results of the Framingham Offspring Study. Arteriosclerosis 1987;7:483-490.
26. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
27. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-146.
28. Sniderman AD, Furberg CD, Keech A et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361:777-780.
29. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002;106(16):2137-2142.
30. Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol 2001;87(10):1174-1180.
31. Ooi TC, Cousins M, Ooi DS et al. Postprandial remnant-like lipoproteins in hypertriglyceridemia. J Clin Endocrinol Metab 2001;86(7):3134-3142.
32. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiol 2005;1(1):39-59.
33. Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the theory of everything. Expert Rev Cardiovasc Ther 2005;3(3):393-404.
34. Bays H. Adiposopathy: role of adipocyte factors in a new paradigm. Expert Rev Cardiovasc Ther 2005;3(2):187-189.
35. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89(2):463-478.
36. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003;6(4):179-188.
37. Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther 2005;3(5):789-820.
38. Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2004;2(4):485-501.
39. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia-current therapies and future agents. Expert Opin Pharmacother 2003;4(11):1901-1938.
40. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001;88(3):270-274.
41. Soedamah-Muthu SS, Colhoun HM, Thomason MJ et al. CARDS Investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003;167(2):243-255.
42. Schaefer EJ, McNamara JR, Tayler T et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002;90(7):689-696.
43. Schaefer EJ,McNamaraJR,TaylerTet al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 2004;93(1):31-39.
44. Miller M, Dolinar C, Cromwell W, Otvos JD. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Am J Cardiol 2001;87(2):232-234.
45. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and lowdensity lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002;90(2):89-94.
46. Rosuvastatin Dose Ranging Study. FDA PI August 2003.
47. Morgan JM, Capuzzi DM, Baksh RI et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003;91(12):1432-1436.
48. Al-Shaer MH. The effects of ezetimibe on the LDL-cholesterol particle number. Cardiovasc Drugs Ther 2004;18(4):327-328.
49. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A communitybased, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-On to Statin for Effectiveness (EASE) Trial. Mayo Clin Proc 2005;80(5):587-595.
50. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men-A nuclear magnetic resonance study. J Atheroscler Thromb 2004;11:278-285.
51. Steinmetz A, Schwartz T, Hehnke U, Kaffarnik H. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. J Cardiovasc Pharmacol 1996;27(4):563-570.
52. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 2004;45(1):174-185.
53. Superko HR, Greenland P, Manchester RA et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol 1992;70(2):135-40.
54. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2005;[Epub ahead of print].
55. CastelliWP, Garrison RJ,WilsonPWet al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986;256:2835-2838.
56. Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the multiple risk factor intervention trial. Prev Med. 1986;15(3):254-273.
57. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(suppl):S11-S20.
58. Goldbourt U, Yaari JS, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8,000 men. Arterioscler Thromb Vasc Biol 1997;17:107-113.
59. Genest J, Jr, McNamara JR, Ordovas JM et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802.
60. Toth PP. High-density lipoprotein and cardiovascular disease. Circulation 2004;109:1809-1812.
61. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.
62. Shai I, Rimm EB, Hankinson SE et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential implications for clinical guidelines. Circulation 2004;110:2824-2830.
63. Toth PP. Reverse cholesterol transport: high-density lipoprotein's magnificent mile. Curr Atheroscler Rep 2003;5:386-393.
64. Eriksson M, Carlson LA, Miettinen TA et al. Stimulation of fecal sterol excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999;100:594-598.
65. Toth, PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol 2005;96(suppl):50 K-58 K.
66. Li X-P, Zhao S-P, Zhang XY, Liu L, Gao M, Zhou Q-C. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol 2000;73:231-236.
67. Barter PJ. Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins. Clin Exp Pharmacol Physiol 1997;24:286-287.
68. Nofer JR, Levkau B, Wolinska I et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 2001; 276:34480-34485.
69. Aviram M, Hardak E,Vaya J et al. Human serum paraoxonases (PON1)Qand R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation 2000;101:2510-2517.
70. Toikka J, Ahotupa M, Viikari J et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL oxidation in healthy young men. Atherosclerosis 1999;147:133-138.
71. Nofer JR,Walter M, Kehrel B et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositidederived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998;18:861-869.
72. Viñals M, Martínez-González J, Badimon L. Regulatory effects of HDL on smooth muscle cell prostacyclin release. Arterioscler Thromb Vasc Biol 1999;19:2405-2411.
73. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139-143.
74. ChapmanMJ,AssmannG, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004;20(8):1253-1268.
75. Mosca L, Appel LJ, Benjamin EJ et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-693.
76. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68-S71.
77. Toth PP. High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects. Disease-a-Month 2001;47(8):365-416.
78. Brooks-Wilson A, Marcil M, Clee SM et al. Mutations in ABCA1 In Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999;4:336-345.
79. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991;84:129-139.
80. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Association of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997;17:1098-1105.
81. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. New Engl J Med 1991;325:373-381.
82. Sweetnam PM, Bolton CH,YarnellJWet al. Associations of theHDL2 andHDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1994;90:769-774.
83. Robins SJ, Collins D,Witters, JT et al., for the VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 2001;106:1585-1591.
84. Syvanne M, Nieminen MS, Frick MH et al., for the Lopid Coronary Angiofraphy Trial Study Group. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL-C. Circulation 1998;98:1993-1999.
85. Davidson MH, Toth PP. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 2004;47:73-104.
86. Grundy SM, Cleeman JI, Merz CN et al., for National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227-239.